23,036,271
Vote Records
25,695
Companies
11,771
Funds
3,902
Managers

Home › Companies › ROCKET PHARMACEUTICALS INC. › 2023-2024

ROCKET PHARMACEUTICALS INC. 2023-2024 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and ROCKET PHARMACEUTICALS INC.’s Form 8-K, filed June 20, 2024 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 13Ballot items
  • 240Asset managers, any item
  • 3,542Fund votes
  • June 13, 2024Meeting date

Results at a glance

Meeting of June 13, 2024: 13 items on ROCKET PHARMACEUTICALS INC.’s Form 8-K, filed June 20, 2024: 3 approved · 10 passed (calculated).

Dissent

Significant dissent: 1 director (28.5% against).

Notable dissent: 1 director (12.1% against).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore ROCKET PHARMACEUTICALS INC. in the interactive database Compare manager voting policies

Official 2023-2024 meeting results reported by ROCKET PHARMACEUTICALS INC.

These tallies are ROCKET PHARMACEUTICALS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 20, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

ROCKET PHARMACEUTICALS INC. — official shareholder meeting results, meeting held June 13, 2024
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Elisabeth Björk, M.D., Ph.D. 67,603,904---- 4,348,3297,857,537 94%Passed (calculated)—
Elect Director: Carsten Boess 71,383,452---- 568,7817,857,537 99.2%Passed (calculated)—
Elect Director: Pedro Granadillo 51,458,742---- 20,493,4917,857,537 72%Passed (calculated)—
Elect Director: Gotham Makker, M.D. 71,537,718---- 414,5157,857,537 99.4%Passed (calculated)—
Elect Director: Fady Malik, M.D., Ph.D. 71,706,448---- 245,7857,857,537 99.7%Passed (calculated)—
Elect Director: Gaurav Shah, M.D. 71,555,239---- 396,9947,857,537 99.4%Passed (calculated)—
Elect Director: David P. Southwell 71,650,603---- 301,6307,857,537 99.6%Passed (calculated)—
Elect Director: Roderick Wong, M.D. 71,278,861---- 673,3727,857,537 99.1%Passed (calculated)—
Elect Director: R. Keith Woods 69,222,478---- 2,729,7557,857,537 96%Passed (calculated)—
Elect Director: Naveen Yalamanchi, M.D. 63,231,665---- 8,720,5687,857,537 88%Passed (calculated)—
2. Ratification of Appointment of Independent Registered Accounting Firm 79,704,80188,79316,176 ---- 99.9%Approved—
3. Non-Binding Advisory Vote on the Compensation of the Company's Named Executive Officers 70,707,9351,134,308109,990 --7,857,537 98%Approved—
4. Approval of Increase in Number of Authorized Shares of Common Stock 79,449,783294,94865,039 --0 99.6%Approved—

Source: ROCKET PHARMACEUTICALS INC., Form 8-K, filed with the SEC on June 20, 2024 — read the filing on EDGAR.

How asset managers voted at the ROCKET PHARMACEUTICALS INC. 2023-2024 meeting

240 asset managers disclosed a vote on at least one ROCKET PHARMACEUTICALS INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: Carsten Boess

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 5 wordings of this item as funds reported it.

99.2% Majority: yes · of votes cast

FOR 99.2%
FOR: 71,383,452WITHHELD: 568,781

Prior year: 98.0% for (June 22, 2023 meeting) ▲ 1.3 pts

Details: description as filed, official tally, votes by 84 asset managers

Description as filed by funds: Election of Directors: Carsten Boess

ROCKET PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Carsten Boess”): 71,383,452 for, 568,781 withheld, per its Form 8-K filed June 20, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a plurality of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 99.2% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 84 asset managers below reported 35,434,802 for, 1,892 withheld.

FOR
FOR: 35,434,802WITHHOLD: 1,892
Largest asset managers voting on “Election of Directors: Carsten Boess” at ROCKET PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard10,108,2130 00For
Putnam5,976,8710 00For
BlackRock2,919,5490 00For
State Street2,692,7370 0284For
T. Rowe Price2,358,6490 00For
Fidelity2,014,6950 00For
JANUS INVESTMENT FUND1,166,5230 00For
HARBOR FUNDS914,9510 00For
Dimensional777,6920 00For
Hartford738,3080 00For
BARON INVESTMENT FUNDS TRUST (f/k/a BARON ASSET FUND)690,2700 00For
Charles Schwab533,0830 00For
MUTUAL FUND SERIES TRUST490,7320 00For
Russell Investments451,1460 00For
FRANKLIN STRATEGIC SERIES345,3460 00For
BARON SELECT FUNDS261,2540 00For
John Hancock188,2350 00For
Jackson National186,7570 00For
Direxion Shares ETF Trust177,8050 00For
Equitable176,5760 00For
Global X164,7220 00For
Mercer Funds159,1110 00For
TIAA158,2080 00For
Victory Capital131,3330 00For
Northwestern Mutual127,1420 00For

Showing the 25 largest of 84 asset managers. All 84 are in the interactive database (link above).

Elect Director: David P. Southwell

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 5 wordings of this item as funds reported it.

99.6% Majority: yes · of votes cast

FOR 99.6%
FOR: 71,650,603WITHHELD: 301,630

Prior year: 92.3% for (June 22, 2023 meeting) ▲ 7.3 pts

Details: description as filed, official tally, votes by 84 asset managers

Description as filed by funds: Election of Directors: David P. Southwell

ROCKET PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: David P. Southwell”): 71,650,603 for, 301,630 withheld, per its Form 8-K filed June 20, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a plurality of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 99.6% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 84 asset managers below reported 35,434,698 for, 1,996 withheld.

FOR
FOR: 35,434,698WITHHOLD: 1,996
Largest asset managers voting on “Election of Directors: David P. Southwell” at ROCKET PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard10,108,2130 00For
Putnam5,976,8710 00For
BlackRock2,919,5490 00For
State Street2,692,6330 0388For
T. Rowe Price2,358,6490 00For
Fidelity2,014,6950 00For
JANUS INVESTMENT FUND1,166,5230 00For
HARBOR FUNDS914,9510 00For
Dimensional777,6920 00For
Hartford738,3080 00For
BARON INVESTMENT FUNDS TRUST (f/k/a BARON ASSET FUND)690,2700 00For
Charles Schwab533,0830 00For
MUTUAL FUND SERIES TRUST490,7320 00For
Russell Investments451,1460 00For
FRANKLIN STRATEGIC SERIES345,3460 00For
BARON SELECT FUNDS261,2540 00For
John Hancock188,2350 00For
Jackson National186,7570 00For
Direxion Shares ETF Trust177,8050 00For
Equitable176,5760 00For
Global X164,7220 00For
Mercer Funds159,1110 00For
TIAA158,2080 00For
Victory Capital131,3330 00For
Northwestern Mutual127,1420 00For

Showing the 25 largest of 84 asset managers. All 84 are in the interactive database (link above).

Elect Director: Fady Malik, M.D., Ph.D.

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 6 wordings of this item as funds reported it.

99.7% Majority: yes · of votes cast

FOR 99.7%
FOR: 71,706,448WITHHELD: 245,785

Prior year: 98.2% for (June 22, 2023 meeting) ▲ 1.5 pts

Details: description as filed, official tally, votes by 84 asset managers

Description as filed by funds: Election of Directors: Fady Malik, M.D., Ph.D.

ROCKET PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Fady Malik, M.D., Ph.D.”): 71,706,448 for, 245,785 withheld, per its Form 8-K filed June 20, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a plurality of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 99.7% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 84 asset managers below reported 35,434,802 for, 1,892 withheld.

FOR
FOR: 35,434,802WITHHOLD: 1,892
Largest asset managers voting on “Election of Directors: Fady Malik, M.D., Ph.D.” at ROCKET PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard10,108,2130 00For
Putnam5,976,8710 00For
BlackRock2,919,5490 00For
State Street2,692,7370 0284For
T. Rowe Price2,358,6490 00For
Fidelity2,014,6950 00For
JANUS INVESTMENT FUND1,166,5230 00For
HARBOR FUNDS914,9510 00For
Dimensional777,6920 00For
Hartford738,3080 00For
BARON INVESTMENT FUNDS TRUST (f/k/a BARON ASSET FUND)690,2700 00For
Charles Schwab533,0830 00For
MUTUAL FUND SERIES TRUST490,7320 00For
Russell Investments451,1460 00For
FRANKLIN STRATEGIC SERIES345,3460 00For
BARON SELECT FUNDS261,2540 00For
John Hancock188,2350 00For
Jackson National186,7570 00For
Direxion Shares ETF Trust177,8050 00For
Equitable176,5760 00For
Global X164,7220 00For
Mercer Funds159,1110 00For
TIAA158,2080 00For
Victory Capital131,3330 00For
Northwestern Mutual127,1420 00For

Showing the 25 largest of 84 asset managers. All 84 are in the interactive database (link above).

Elect Director: Gaurav Shah, M.D.

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 6 wordings of this item as funds reported it.

99.4% Majority: yes · of votes cast

FOR 99.4%
FOR: 71,555,239WITHHELD: 396,994

Prior year: 98.0% for (June 22, 2023 meeting) ▲ 1.4 pts

Details: description as filed, official tally, votes by 84 asset managers

Description as filed by funds: Election of Directors: Gaurav Shah, M.D.

ROCKET PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Gaurav Shah, M.D.”): 71,555,239 for, 396,994 withheld, per its Form 8-K filed June 20, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a plurality of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 99.4% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 84 asset managers below reported 35,390,698 for, 45,996 withheld.

FOR
FOR: 35,390,698WITHHOLD: 45,996
Largest asset managers voting on “Election of Directors: Gaurav Shah, M.D.” at ROCKET PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard10,108,2130 00For
Putnam5,976,8710 00For
BlackRock2,919,5490 00For
State Street2,692,6330 0388For
T. Rowe Price2,358,6490 00For
Fidelity2,014,6950 00For
JANUS INVESTMENT FUND1,166,5230 00For
HARBOR FUNDS914,9510 00For
Dimensional777,6920 00For
Hartford738,3080 00For
BARON INVESTMENT FUNDS TRUST (f/k/a BARON ASSET FUND)690,2700 00For
Charles Schwab533,0830 00For
MUTUAL FUND SERIES TRUST490,7320 00For
Russell Investments451,1460 00For
FRANKLIN STRATEGIC SERIES345,3460 00For
BARON SELECT FUNDS261,2540 00For
John Hancock188,2350 00For
Jackson National186,7570 00For
Direxion Shares ETF Trust177,8050 00For
Equitable176,5760 00For
Global X164,7220 00For
Mercer Funds159,1110 00For
TIAA158,2080 00For
Victory Capital131,3330 00For
Northwestern Mutual127,1420 00For

Showing the 25 largest of 84 asset managers. All 84 are in the interactive database (link above).

Elect Director: Gotham Makker, M.D.

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 6 wordings of this item as funds reported it.

99.4% Majority: yes · of votes cast

FOR 99.4%
FOR: 71,537,718WITHHELD: 414,515

Prior year: 98.0% for (June 22, 2023 meeting) ▲ 1.4 pts

Details: description as filed, official tally, votes by 84 asset managers

Description as filed by funds: Election of Directors: Gotham Makker, M.D.

ROCKET PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Gotham Makker, M.D.”): 71,537,718 for, 414,515 withheld, per its Form 8-K filed June 20, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a plurality of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 99.4% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 84 asset managers below reported 35,390,698 for, 45,996 withheld.

FOR
FOR: 35,390,698WITHHOLD: 45,996
Largest asset managers voting on “Election of Directors: Gotham Makker, M.D.” at ROCKET PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard10,108,2130 00For
Putnam5,976,8710 00For
BlackRock2,919,5490 00For
State Street2,692,6330 0388For
T. Rowe Price2,358,6490 00For
Fidelity2,014,6950 00For
JANUS INVESTMENT FUND1,166,5230 00For
HARBOR FUNDS914,9510 00For
Dimensional777,6920 00For
Hartford738,3080 00For
BARON INVESTMENT FUNDS TRUST (f/k/a BARON ASSET FUND)690,2700 00For
Charles Schwab533,0830 00For
MUTUAL FUND SERIES TRUST490,7320 00For
Russell Investments451,1460 00For
FRANKLIN STRATEGIC SERIES345,3460 00For
BARON SELECT FUNDS261,2540 00For
John Hancock188,2350 00For
Jackson National186,7570 00For
Direxion Shares ETF Trust177,8050 00For
Equitable176,5760 00For
Global X164,7220 00For
Mercer Funds159,1110 00For
TIAA158,2080 00For
Victory Capital131,3330 00For
Northwestern Mutual127,1420 00For

Showing the 25 largest of 84 asset managers. All 84 are in the interactive database (link above).

Elect Director: Naveen Yalamanchi, M.D.

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 6 wordings of this item as funds reported it.

88% Majority: yes · of votes cast

FOR 88%
FOR: 63,231,665WITHHELD: 8,720,568

Prior year: 68.7% for (June 22, 2023 meeting) ▲ 19.2 pts

Details: description as filed, official tally, votes by 84 asset managers

Description as filed by funds: Election of Directors: Naveen Yalamanchi, M.D.

ROCKET PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Naveen Yalamanchi, M.D.”): 63,231,665 for, 8,720,568 withheld, per its Form 8-K filed June 20, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a plurality of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 88% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 84 asset managers below reported 30,913,621 for, 4,523,073 withheld.

FOR
FOR: 30,913,621WITHHOLD: 4,523,073
Largest asset managers voting on “Election of Directors: Naveen Yalamanchi, M.D.” at ROCKET PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard10,108,2130 00For
Putnam5,976,8710 00For
BlackRock00 02,919,549Withhold
State Street2,692,7370 0284For
T. Rowe Price2,358,6490 00For
Fidelity1,982,9220 031,773For
JANUS INVESTMENT FUND1,166,5230 00For
HARBOR FUNDS914,9510 00For
Dimensional777,6920 00For
Hartford738,3080 00For
BARON INVESTMENT FUNDS TRUST (f/k/a BARON ASSET FUND)690,2700 00For
Charles Schwab00 0533,083Withhold
MUTUAL FUND SERIES TRUST490,7320 00For
Russell Investments451,1460 00For
FRANKLIN STRATEGIC SERIES00 0345,346Withhold
BARON SELECT FUNDS261,2540 00For
John Hancock188,2350 00For
Jackson National186,7570 00For
Direxion Shares ETF Trust177,8050 00For
Equitable79,6990 096,877Mixed
Global X00 0164,722Withhold
Mercer Funds159,1110 00For
TIAA158,2080 00For
Victory Capital131,3330 00For
Northwestern Mutual127,1420 00For

Showing the 25 largest of 84 asset managers. All 84 are in the interactive database (link above).

Elect Director: Pedro Granadillo

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 5 wordings of this item as funds reported it.

72% Majority: yes · of votes cast

FOR 72%WITHHELD
FOR: 51,458,742WITHHELD: 20,493,491

Prior year: 95.1% for (June 22, 2023 meeting) ▼ 23.6 pts

Details: description as filed, official tally, votes by 84 asset managers

Description as filed by funds: Election of Directors: Pedro Granadillo

ROCKET PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Pedro Granadillo”): 51,458,742 for, 20,493,491 withheld, per its Form 8-K filed June 20, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a plurality of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 72% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 84 asset managers below reported 26,568,323 for, 73 against, 8,868,298 withheld.

FORWITHHOLD
FOR: 26,568,323AGAINST: 73WITHHOLD: 8,868,298
Largest asset managers voting on “Election of Directors: Pedro Granadillo” at ROCKET PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard10,108,2130 00For
Putnam5,976,8710 00For
BlackRock2,919,5490 00For
State Street2,8450 02,690,176Withhold
T. Rowe Price2,358,6490 00For
Fidelity1,438,5800 0576,115Mixed
JANUS INVESTMENT FUND703,5510 0462,972Mixed
HARBOR FUNDS49,2960 0865,655Mixed
Dimensional00 0777,692Withhold
Hartford738,3080 00For
BARON INVESTMENT FUNDS TRUST (f/k/a BARON ASSET FUND)00 0690,270Withhold
Charles Schwab00 0533,083Withhold
MUTUAL FUND SERIES TRUST490,7320 00For
Russell Investments451,1460 00For
FRANKLIN STRATEGIC SERIES00 0345,346Withhold
BARON SELECT FUNDS00 0261,254Withhold
John Hancock164,8230 023,412Mixed
Jackson National172,2000 014,557Mixed
Direxion Shares ETF Trust00 0177,805Withhold
Equitable110,2860 066,290Mixed
Global X00 0164,722Withhold
Mercer Funds00 0159,111Withhold
TIAA00 0158,208Withhold
Victory Capital1,9640 0129,369Withhold
Northwestern Mutual127,1420 00For

Showing the 25 largest of 84 asset managers. All 84 are in the interactive database (link above).

Elect Director: R. Keith Woods

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 5 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%
FOR: 69,222,478WITHHELD: 2,729,755
Details: description as filed, official tally, votes by 84 asset managers

Description as filed by funds: Election of Directors: R. Keith Woods

ROCKET PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: R. Keith Woods”): 69,222,478 for, 2,729,755 withheld, per its Form 8-K filed June 20, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a plurality of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 96% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 84 asset managers below reported 28,194,612 for, 7,242,082 withheld.

FORWITHHOLD
FOR: 28,194,612WITHHOLD: 7,242,082
Largest asset managers voting on “Election of Directors: R. Keith Woods” at ROCKET PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard10,108,2130 00For
Putnam00 05,976,871Withhold
BlackRock2,919,5490 00For
State Street2,693,0210 00For
T. Rowe Price2,358,6490 00For
Fidelity1,438,5800 0576,115Mixed
JANUS INVESTMENT FUND1,166,5230 00For
HARBOR FUNDS914,9510 00For
Dimensional777,6920 00For
Hartford738,3080 00For
BARON INVESTMENT FUNDS TRUST (f/k/a BARON ASSET FUND)690,2700 00For
Charles Schwab00 0533,083Withhold
MUTUAL FUND SERIES TRUST490,7320 00For
Russell Investments451,1460 00For
FRANKLIN STRATEGIC SERIES345,3460 00For
BARON SELECT FUNDS261,2540 00For
John Hancock188,2350 00For
Jackson National186,7570 00For
Direxion Shares ETF Trust177,8050 00For
Equitable176,5760 00For
Global X164,7220 00For
Mercer Funds159,1110 00For
TIAA158,2080 00For
Victory Capital131,3330 00For
Northwestern Mutual127,1420 00For

Showing the 25 largest of 84 asset managers. All 84 are in the interactive database (link above).

Elect Director: Roderick Wong, M.D.

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 6 wordings of this item as funds reported it.

99.1% Majority: yes · of votes cast

FOR 99.1%
FOR: 71,278,861WITHHELD: 673,372

Prior year: 96.9% for (June 22, 2023 meeting) ▲ 2.1 pts

Details: description as filed, official tally, votes by 84 asset managers

Description as filed by funds: Election of Directors: Roderick Wong, M.D.

ROCKET PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Roderick Wong, M.D.”): 71,278,861 for, 673,372 withheld, per its Form 8-K filed June 20, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a plurality of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 99.1% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 84 asset managers below reported 35,350,766 for, 85,928 withheld.

FOR
FOR: 35,350,766WITHHOLD: 85,928
Largest asset managers voting on “Election of Directors: Roderick Wong, M.D.” at ROCKET PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard10,108,2130 00For
Putnam5,976,8710 00For
BlackRock2,919,5490 00For
State Street2,692,6330 0388For
T. Rowe Price2,358,6490 00For
Fidelity2,014,6950 00For
JANUS INVESTMENT FUND1,166,5230 00For
HARBOR FUNDS914,9510 00For
Dimensional777,6920 00For
Hartford738,3080 00For
BARON INVESTMENT FUNDS TRUST (f/k/a BARON ASSET FUND)690,2700 00For
Charles Schwab533,0830 00For
MUTUAL FUND SERIES TRUST490,7320 00For
Russell Investments451,1460 00For
FRANKLIN STRATEGIC SERIES345,3460 00For
BARON SELECT FUNDS261,2540 00For
John Hancock188,2350 00For
Jackson National186,7570 00For
Direxion Shares ETF Trust177,8050 00For
Equitable176,5760 00For
Global X164,7220 00For
Mercer Funds159,1110 00For
TIAA158,2080 00For
Victory Capital131,3330 00For
Northwestern Mutual127,1420 00For

Showing the 25 largest of 84 asset managers. All 84 are in the interactive database (link above).

Elect Director: Elisabeth Björk, M.D., Ph.D.

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 6 wordings of this item as funds reported it.

94% Majority: yes · of votes cast

FOR 94%
FOR: 67,603,904WITHHELD: 4,348,329

Prior year: 91.5% for (June 22, 2023 meeting) ▲ 2.4 pts

Details: description as filed, official tally, votes by 80 asset managers

Description as filed by funds: Election of Directors: Elisabeth Bjork, M.D., Ph.D.

ROCKET PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Elisabeth Björk, M.D., Ph.D.”): 67,603,904 for, 4,348,329 withheld, per its Form 8-K filed June 20, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a plurality of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 94% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 80 asset managers below reported 32,663,569 for, 2,663,799 withheld.

FOR
FOR: 32,663,569WITHHOLD: 2,663,799
Largest asset managers voting on “Election of Directors: Elisabeth Bjork, M.D., Ph.D.” at ROCKET PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard10,108,2130 00For
Putnam5,976,8710 00For
BlackRock2,919,5490 00For
State Street55,7240 02,637,297Withhold
T. Rowe Price2,358,6490 00For
Fidelity2,014,6950 00For
JANUS INVESTMENT FUND1,166,5230 00For
HARBOR FUNDS914,9510 00For
Dimensional777,6920 00For
Hartford738,3080 00For
BARON INVESTMENT FUNDS TRUST (f/k/a BARON ASSET FUND)690,2700 00For
Charles Schwab533,0830 00For
MUTUAL FUND SERIES TRUST490,7320 00For
Russell Investments451,1460 00For
FRANKLIN STRATEGIC SERIES345,3460 00For
BARON SELECT FUNDS261,2540 00For
John Hancock188,2350 00For
Jackson National186,7570 00For
Direxion Shares ETF Trust177,8050 00For
Equitable176,5760 00For
Global X164,7220 00For
Mercer Funds159,1110 00For
TIAA158,2080 00For
Victory Capital131,3330 00For
Northwestern Mutual127,1420 00For

Showing the 25 largest of 80 asset managers. All 80 are in the interactive database (link above).

Approval of Increase in Number of Authorized Shares of Common Stock

Official resultCAPITAL STRUCTUREReported outcome: Approved

Combines 6 wordings of this item as funds reported it.

99.6% Approved · of votes cast

FOR 99.6%
FOR: 79,449,783AGAINST: 294,948
Details: description as filed, official tally, votes by 84 asset managers

Description as filed by funds: Approval of an amendment to the Company's Seventh Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock.

ROCKET PHARMACEUTICALS INC.’s own tally for this item (“4. Approval of Increase in Number of Authorized Shares of Common Stock”): 79,449,783 for, 294,948 against — passed, per its Form 8-K filed June 20, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal Four - Approval of Increase in Number of Authorized Shares of Common Stock The Company's stockholders approved an Amendment to the Company's Seventh Amended and Restated Certificate of Incorporation to increase the authorized number of shares of common stock from 120,000,000 shares to 180,…”
Support: 99.6% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 84 asset managers below reported 35,392,694 for, 44,000 against.

FOR
FOR: 35,392,694AGAINST: 44,000
Largest asset managers voting on “Approval of an amendment to the Company's Seventh Amended and Restated Certificate of Incorporation to increas” at ROCKET PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard10,108,2130 00For
Putnam5,976,8710 00For
BlackRock2,919,5490 00For
State Street2,693,0210 00For
T. Rowe Price2,358,6490 00For
Fidelity2,014,6950 00For
JANUS INVESTMENT FUND1,166,5230 00For
HARBOR FUNDS914,9510 00For
Dimensional777,6920 00For
Hartford738,3080 00For
BARON INVESTMENT FUNDS TRUST (f/k/a BARON ASSET FUND)690,2700 00For
Charles Schwab533,0830 00For
MUTUAL FUND SERIES TRUST490,7320 00For
Russell Investments451,1460 00For
FRANKLIN STRATEGIC SERIES345,3460 00For
BARON SELECT FUNDS261,2540 00For
John Hancock188,2350 00For
Jackson National186,7570 00For
Direxion Shares ETF Trust177,8050 00For
Equitable176,5760 00For
Global X164,7220 00For
Mercer Funds159,1110 00For
TIAA158,2080 00For
Victory Capital131,3330 00For
Northwestern Mutual127,1420 00For

Showing the 25 largest of 84 asset managers. All 84 are in the interactive database (link above).

Non-Binding Advisory Vote on the Compensation of the Company's Named Executive Officers

Official resultFund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 11 wordings of this item as funds reported it.

98% Approved · of votes cast

FOR 98%
FOR: 70,707,935AGAINST: 1,134,308

Prior year: 83.6% for (June 22, 2023 meeting) ▲ 14.8 pts

Details: description as filed, official tally, votes by 240 asset managers

Description as filed by funds: APPROVAL OF THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS, ON A NON-BINDING, ADVISORY BASIS.

ROCKET PHARMACEUTICALS INC.’s own tally for this item (“3. Non-Binding Advisory Vote on the Compensation of the Company's Named Executive Officers”): 70,707,935 for, 1,134,308 against — passed, per its Form 8-K filed June 20, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal Three - Non-Binding Advisory Vote on the Compensation of the Company's Named Executive Officers The Company's stockholders approved, on a non-binding, advisory basis, the compensation of the Company's named executive officers, as disclosed in the 2024 Proxy Statement pursuant to Section 14…”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 81 asset managers voting on “APPROVAL OF THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS, ON A NON-BINDING, ADVISORY BASIS.” at ROCKET PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard10,108,2130 00For
Putnam5,976,8710 00For
BlackRock2,919,5490 00For
State Street2,693,0210 00For
T. Rowe Price2,358,6490 00For
Fidelity2,014,6950 00For
JANUS INVESTMENT FUND1,166,5230 00For
HARBOR FUNDS914,9510 00For
Dimensional777,6920 00For
Hartford738,3080 00For
BARON INVESTMENT FUNDS TRUST (f/k/a BARON ASSET FUND)690,2700 00For
Charles Schwab533,0830 00For
MUTUAL FUND SERIES TRUST490,7320 00For
Russell Investments451,1460 00For
FRANKLIN STRATEGIC SERIES345,3460 00For
BARON SELECT FUNDS261,2540 00For
John Hancock188,2350 00For
Jackson National186,7570 00For
Direxion Shares ETF Trust177,8050 00For
Equitable176,5760 00For
Global X164,7220 00For
Mercer Funds159,1110 00For
TIAA158,2080 00For
Victory Capital131,3330 00For
Northwestern Mutual127,1420 00For

Fund voting reports, all 81 managers: 35,370,555 for, 20,884 against. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 181 asset managers voting on “APPROVAL OF THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS, ON A NON-BINDING, ADVISORY BASIS.” at ROCKET PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
RTW INVESTMENTS, LP14,343,5710 00For
Wellington8,071,2720 00For
State Street3,846,4340 00For
T. Rowe Price2,988,6480 00For
WESTFIELD CAPITAL MANAGEMENT CO LP2,734,7550 00For
MAVERICK CAPITAL LTD2,049,0670 00For
Janus Henderson2,011,8150 00For
GEODE CAPITAL MANAGEMENT, LLC1,499,6720 00For
Boxer Capital, LLC1,466,0510 00For
BlackRock1,399,2250 00For
PICTET ASSET MANAGEMENT SA1,189,8150 00For
Logos Global Management LP1,150,0000 00For
FRANKLIN ADVISERS INC1,115,8820 00For
Novo Holdings A/S1,100,0000 00For
BAMCO INC /NY/951,5240 00For
Avidity Partners Management LP850,0200 00For
Putnam751,4850 00For
JPMorgan657,2190 00For
Fidelity578,3520 00For
Charles Schwab533,0830 00For
SCHRODER INVESTMENT MANAGEMENT GROUP0418,745 00Against
TANG CAPITAL MANAGEMENT LLC404,7070 00For
Northern Trust347,52456 00For
Citadel342,0310 00For
ACUTA CAPITAL PARTNERS, LLC330,5100 00For

Institutional-manager reports, all 181 managers: 55,289,826 for, 966,046 against, 264 withheld. Showing the 25 largest; every one is in the interactive database (link above).

Ratification of Appointment of Independent Registered Accounting Firm

Official resultAUDIT-RELATEDReported outcome: Approved

Combines 4 wordings of this item as funds reported it.

99.9% Approved · of votes cast

FOR 99.9%
FOR: 79,704,801AGAINST: 88,793

Prior year: 98.7% for (June 22, 2023 meeting) ▲ 1.2 pts

Details: description as filed, official tally, votes by 83 asset managers

Description as filed by funds: Ratification of the appointment of EisnerAmper LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024.

ROCKET PHARMACEUTICALS INC.’s own tally for this item (“2. Ratification of Appointment of Independent Registered Accounting Firm”): 79,704,801 for, 88,793 against — passed, per its Form 8-K filed June 20, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal Two - Ratification of Appointment of Independent Registered Accounting Firm The Company's stockholders ratified the appointment of EisnerAmper LLP as the Company's independent registered accounting firm for the fiscal year ending December 31, 2024 by the following votes:”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 83 asset managers below reported 35,434,710 for, 439 against.

FOR
FOR: 35,434,710AGAINST: 439
Largest asset managers voting on “Ratification of the appointment of EisnerAmper LLP as the Company's independent registered public accounting f” at ROCKET PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard10,108,2130 00For
Putnam5,976,8710 00For
BlackRock2,919,5490 00For
State Street2,692,582439 00For
T. Rowe Price2,358,6490 00For
Fidelity2,014,6950 00For
JANUS INVESTMENT FUND1,166,5230 00For
HARBOR FUNDS914,9510 00For
Dimensional777,6920 00For
Hartford738,3080 00For
BARON INVESTMENT FUNDS TRUST (f/k/a BARON ASSET FUND)690,2700 00For
Charles Schwab533,0830 00For
MUTUAL FUND SERIES TRUST490,7320 00For
Russell Investments451,1460 00For
FRANKLIN STRATEGIC SERIES345,3460 00For
BARON SELECT FUNDS261,2540 00For
John Hancock188,2350 00For
Jackson National186,7570 00For
Direxion Shares ETF Trust177,8050 00For
Equitable176,5760 00For
Global X164,7220 00For
Mercer Funds159,1110 00For
TIAA158,2080 00For
Victory Capital131,3330 00For
Northwestern Mutual127,1420 00For

Showing the 25 largest of 83 asset managers. All 83 are in the interactive database (link above).

Largest ROCKET PHARMACEUTICALS INC. shareholders voting in 2023-2024

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 90,646,590 shares outstanding at the time of that meeting.

Fund voting reports: top ROCKET PHARMACEUTICALS INC. shareholders by shares voted on “APPROVAL OF THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS, ON A NON-BINDING…”, 2023-2024
#Asset manager % of shares outstanding
1Vanguard 11.15%
2Putnam 6.59%
3BlackRock 3.22%
4State Street 2.97%
5T. Rowe Price 2.60%
6Fidelity 2.22%
7JANUS INVESTMENT FUND 1.29%
8HARBOR FUNDS 1.01%
9Dimensional 0.86%
10Hartford 0.81%
Institutional-manager reports: top ROCKET PHARMACEUTICALS INC. shareholders by shares voted on “APPROVAL OF THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS, ON A NON-BINDING…”, 2023-2024
#Asset manager % of shares outstanding
1RTW INVESTMENTS, LP 15.82%
2Wellington 8.90%
3State Street 4.24%
4T. Rowe Price 3.30%
5WESTFIELD CAPITAL MANAGEMENT CO LP 3.02%
6MAVERICK CAPITAL LTD 2.26%
7Janus Henderson 2.22%
8GEODE CAPITAL MANAGEMENT, LLC 1.65%
9Boxer Capital, LLC 1.62%
10BlackRock 1.54%

Reported ROCKET PHARMACEUTICALS INC. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

ROCKET PHARMACEUTICALS INC. holdings and ownership disclosed for the 2023-2024 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
Roderick Wong, M.D.18,371,873 20.27%Proxy statement (DEF 14A), proxy filed April 29, 2024
RTW Investments, LP18,188,457 20.07%Proxy statement (DEF 14A), proxy filed April 29, 2024
Wellington Management9,156,099 10.10%Form 13F, quarter ended March 31, 2024
BlackRock7,114,371 7.85%Form 13F, quarter ended March 31, 2024
Vanguard Group6,892,204 7.60%Form 13F, quarter ended March 31, 2024
State Street4,193,077 4.63%Form 13F, quarter ended March 31, 2024
Morgan Stanley3,647,039 4.02%Form 13F, quarter ended March 31, 2024
T. Rowe Price2,943,160 3.25%Form 13F, quarter ended March 31, 2024
Gaurav Shah, M.D.2,819,758 3.11%Proxy statement (DEF 14A), proxy filed April 29, 2024
Citadel Advisors2,529,813 2.79%Form 13F, quarter ended March 31, 2024

Percentages above are of 90,646,590 shares outstanding, as reported by ROCKET PHARMACEUTICALS INC. on its Form 10-Q dated March 31, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At ROCKET PHARMACEUTICALS INC.'s shareholder meeting held June 13, 2024, in the 2023-2024 proxy season, 240 asset managers reported votes on at least one of its 13 ballot items in their SEC Form N-PX filings, covering 3,542 separate fund positions. On the most widely held item on that ballot — APPROVAL OF THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS, ON A NON-BINDING… — ROCKET PHARMACEUTICALS INC.'s filing reports the proposal as approved, with 98% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: ROCKET PHARMACEUTICALS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 20, 2024.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from ROCKET PHARMACEUTICALS INC.’s 10-Q dated March 31, 2024. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

ROCKET PHARMACEUTICALS INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.

Cite this page

Proxy Votes Now, “ROCKET PHARMACEUTICALS (RCKT) 2024 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/rocket-pharmaceuticals-inc/2024 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.